Alchemy Labs Reports 17% Revenue Growth and 38.7% Gross Margin in Second Quarter 2026

Losses are widening despite revenue growth and a major post-quarter IPO cash injection.

What the company is saying

Alchemy Labs Inc. positions its Q2 2026 update as a story of growth and momentum, emphasizing a 16.9% year-over-year revenue increase and a return to positive gross margin. The company highlights operational milestones, such as launching six ExoShield ULTRA Pro kit models and completing Phase One of the NATO DIANA Accelerator Programme, but provides no quantitative evidence for these claims. Management frames the $13.7 million IPO as a transformative event, stating it will accelerate commercialization of ExoShield and Crypsis. The announcement stresses improved product availability and business development in defence, using confident language but offering only high-level descriptions. Non-financial achievements are presented as validation of the company’s trajectory, but without measurable results. The tone is upbeat and forward-looking, with CEO Khanjan Desai cited as the key spokesperson.

What the data suggests

The financials show Q2 2026 revenue at $581,027, up 16.9% from $496,871 a year earlier, with ExoShield contributing $509,195 (2.5% growth) and Crypsis adding $71,382 (from zero last year). Gross profit improved to $224,803, reversing a $1,177 loss in Q2 2025, and gross margin rose sharply from -0.2% to 38.7%. Despite these gains, operating loss widened to $1,188,682 from $761,845, and net loss increased to $1,573,556 ($0.06 per share) from $1,148,152 ($0.03 per share). Cash at quarter-end was $1,259,817, but this excludes the $13,738,447 raised in the July 9, 2026 IPO. The data confirms top-line and margin progress, but also reveals that costs are rising faster than revenues, and there is no evidence of operational leverage. Non-financial claims about product launches, business development, and agreements lack supporting metrics or financial impact. The disclosures are clear for headline figures, but segment and expense detail is limited.

Analysis

The announcement presents a positive tone, highlighting revenue growth, gross margin improvement, and the completion of an IPO. However, the underlying financials show that both operating and net losses have increased year-over-year, indicating that profitability is deteriorating despite top-line gains. While some operational milestones (product launches, program completions, agreements) are mentioned, these are not supported by quantitative evidence or detailed outcomes, making them more promotional than substantive. The capital raise is significant, but there is no immediate earnings impact disclosed, and the stated use of proceeds is to accelerate commercialization, which is inherently forward-looking and uncertain. The gap between narrative and evidence is most apparent in the unsupported claims of business development and product validation, which lack measurable results. Overall, the data supports a weak_positive signal due to revenue and margin improvement, but the hype level is moderate because of the promotional framing and lack of profitability.

Risk flags

• ●Operating and net losses are increasing despite revenue and gross margin improvements, indicating that the company’s cost structure is outpacing its growth. This raises questions about scalability and the timeline to profitability.
• ●The company’s operational claims—such as product launches, program completions, and business development—are not supported by quantitative data or measurable outcomes. This lack of transparency makes it difficult to assess the true commercial impact of these activities.
• ●The post-quarter IPO raises $13,738,447 in new capital, but the announcement does not specify how quickly or effectively these funds will be deployed, nor does it provide a breakdown of anticipated returns or milestones. This introduces execution risk around capital allocation and commercialization.
• ●Cash as of June 30, 2026, was only $1,259,817, suggesting the company was reliant on the IPO to fund ongoing operations. If commercialization efforts do not yield rapid revenue growth or margin improvement, future dilution or liquidity risk could re-emerge.

Bottom line

Alchemy Labs Inc. is growing revenue and has improved gross margin, but its losses are accelerating and there is no evidence yet of operational scale or profitability. The $13.7 million IPO gives the company a cash runway, but management’s claims about business development and product launches are not substantiated by contracts, revenue, or customer adoption data. Investors should treat the upbeat narrative with caution until the company demonstrates that new capital translates into measurable commercial wins or a path to breakeven. The most important takeaway is that, while the balance sheet is now stronger, the core business remains unproven at scale and the risk of ongoing losses is high unless operational leverage materializes.

Announcement summary

(TSXV: ALCH) Alchemy Labs Inc. reported financial results for the three months ended June 30, 2026, with revenue of $581,027 compared to $496,871 in Q2, 2025, reflecting a 16.9% increase. ExoShield revenue was $509,195, compared to $496,871 in Q2, 2025, a 2.5% increase, while Crypsis revenue was $71,382 compared to $Nil in Q2, 2025. Gross profit was $224,803, representing a gross margin of 38.7%, compared to a gross loss of $1,177 and gross margin of (0.2%) in Q2 2025. Operating loss was $1,188,682 compared to an operating loss of $761,845 in Q2, 2025. Net loss was $1,573,556, or ($0.06) per share, compared to a net loss of $1,148,152, or ($0.03) per share in Q2, 2025. Cash and cash equivalents were $1,259,817 as at June 30, 2026. Subsequent to quarter-end, on July 9, 2026, the Company completed its initial public offering, raising gross proceeds of $13,738,447 through the issuance of 13,738,447 units at $1.00 per unit.

Disagree with this article?